Skip Navigation


Brain Advance Access originally published online on June 17, 2008
Brain 2008 131(8):2071-2083; doi:10.1093/brain/awn117
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
131/8/2071    most recent
awn117v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mazarati, A.
Right arrow Articles by Sankar, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mazarati, A.
Right arrow Articles by Sankar, R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine

Andréy Mazarati1, Prabha Siddarth2, Roger A. Baldwin3, Don Shin1, Rochelle Caplan1,2 and Raman Sankar1,4

1Department of Pediatrics, 2Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 3Research, West Los Angeles Veterans Administration Medical Center and 4Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Correspondence to: Andrey Mazarati, MD, PhD, David Geffen School of Medicine at UCLA, Room 22-474 MDCC (175217), Los Angeles, CA 90095-1752, USA E-mail: mazarati{at}ucla.edu

Depression represents one of the most common comorbidities in patients with epilepsy. However, the mechanisms of depression in epilepsy patients are poorly understood. Establishment of animal models of this comorbidity is critical for both understanding the mechanisms of the condition, and for preclinical development of effective therapies. The current study examined whether a commonly used animal model of temporal lobe epilepsy (TLE) is characterized by behavioural and biochemical alterations involved in depression. Male Wistar rats were subjected to LiCl and pilocarpine status epilepticus (SE). The development of chronic epileptic state was confirmed by the presence of spontaneous seizures and by enhanced brain excitability. Post-SE animals exhibited increase in immobility time under conditions of forced swim test (FST) which was indicative of despair-like state, and loss of taste preference in saccharin solution consumption test which pointed to the symptomatic equivalence of anhedonia. Biochemical studies revealed compromised serotonergic transmission in the raphe-hippocampal serotonergic pathway: decrease of serotonin (5-HT) concentration and turnover in the hippocampus, measured by high performance liquid chromatography, and decrease of 5-HT release from the hippocampus in response to raphe stimulation, measured by fast cyclic voltammetry. Administration of fluoxetine (FLX, 20 mg/kg/day for 10 days) to naive animals significantly shortened immobility time under conditions of FST, and inhibited 5-HT turnover in the hippocampus. In post-SE rats FLX treatment led to a further decrease of hippocampal 5-HT turnover; however, performance in FST was not improved. At the same time, FLX reversed SE-induced increase in brain excitability. In summary, our studies provide initial evidence that post-SE model of TLE might serve as a model of the comorbidity of epilepsy and depression. The finding that behavioural equivalents of depression were resistant to an antidepressant medication suggested that depression in epilepsy might have distinct underlying mechanisms beyond alterations in serotonergic pathways.

Key Words: comorbidity; depression; epilepsy; hippocampus; serotonin

Abbreviations: 5-HT, serotonin; 5-HIAA, 5-hydroxyindolacetic acid; ADT, afterdischarge threshold; ADD, afterdischarge duration; FCV, fast cyclic voltammetry; FLX, fluoxetine; FST, forced swim test; HPLC, high performance liquid chromatography; PCA, parachloroamphetamine; SE, status epilepticus; SERT, serotonin transporter; SSRI, selective serotonin reuptake inhibitors; TLE, temporal lobe epilepsy.

Received January 24, 2008. Revised March 26, 2008. Accepted May 12, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.